Cargando…

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis

OBJECTIVE: To quantify peripheral nerve lesions in symptomatic and asymptomatic hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PNP) by analyzing the magnetization transfer ratio (MTR) of the sciatic nerve, and to test its potential as a novel biomarker for macromolecular changes. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kollmer, Jennifer, Hegenbart, Ute, Kimmich, Christoph, Hund, Ernst, Purrucker, Jan C., Hayes, John M., Lentz, Stephen I., Sam, Georges, Jende, Johann M. E., Schönland, Stefan O., Bendszus, Martin, Heiland, Sabine, Weiler, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261747/ https://www.ncbi.nlm.nih.gov/pubmed/32333729 http://dx.doi.org/10.1002/acn3.51049

Ejemplares similares

MR-Neurography of the sural nerve in patients with hereditary amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2015)

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
por: Kollmer, Jennifer, et al.
Publicado: (2015)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2022)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis
por: Hund, Ernst
Publicado: (2012)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
por: Skrahina, Volha, et al.
Publicado: (2021)

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
por: Cortese, Andrea, et al.
Publicado: (2017)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2020)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature
por: Dohrn, Maike F., et al.
Publicado: (2020)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study
por: Inês, Mónica, et al.
Publicado: (2020)

Corrigendum: Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2022)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy
por: Gasparotti, Roberto, et al.
Publicado: (2023)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
por: Hein, Selina, et al.
Publicado: (2021)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
por: Vegezzi, Elisa, et al.
Publicado: (2022)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Hereditary Transthyretin Amyloidosis in Eight Chinese Families
por: Meng, Ling-Chao, et al.
Publicado: (2015)

Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019)

Hereditary transthyretin amyloidosis: a case report
por: Lee, Angela, et al.
Publicado: (2022)

Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis
por: Lin, Xiaochen, et al.
Publicado: (2021)

Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study
por: Yarlas, Aaron, et al.
Publicado: (2021)

Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center
por: Sequeira, Vanessa Cristina Cunha, et al.
Publicado: (2021)

Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
por: Dohrn, Maike F., et al.
Publicado: (2021)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019)

Characteristics of South Korean Patients with Hereditary Transthyretin Amyloidosis
por: Choi, Kyomin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8h2ap4m9rih3ql0c543d1mdj94